For how we live.
I-SPY2.2 tested trastuzumab-deruxtecan plus rilvegostomig before surgery in high-risk HER2-negative breast cancer. In immune-positive tumours 54% had a complete response, and most of them avoided anthracyclines.
In a 98-patient French trial, six-monthly rituximab did not extend remission beyond daily azathioprine in this rare eosinophilic vasculitis — and recipients had more severe infections.
GSK's PD-1 blocker won accelerated US approval on 19 October for previously untreated stage II/III dMMR rectal cancer. In the single-arm AZUR-1 trial, most patients avoided surgery, radiation and chemotherapy.
In 120 older adults with acute myeloid leukaemia, adding midostaurin to two-drug therapy did not raise remission rates overall (72% vs 68%), but a small FLT3-mutated subgroup lived longer.
In 108 people with Parkinson's, diffusion MRI found that damage to cholinergic pathways running from a deep-brain nucleus tracked worse cognition — and was most marked in those with dementia.
A single-centre randomised trial found the Bergen 4-day treatment cut obsessive-compulsive symptoms far more than an unguided internet CBT programme, with 61% responding at three months versus 25%.
In 143 people with poorly controlled type 1 diabetes, a system that prompts injections through glucose-sensor alerts was non-inferior to standard monitoring — and acting on the alerts drove the benefit.
A six-site randomised trial of point-of-care high-sensitivity troponin cut emergency-department length of stay by 47 minutes, with no change in 30-day heart attacks or cardiac deaths.
In 1,429 high-risk breast-cancer patients, a 16-dose regimen covering the internal mammary nodes matched the standard 25-dose course for recurrence and caused far less severe skin damage.
In 947 Chinese children followed for ten years, those with insulin resistance despite normal blood sugar had a 4.3-fold higher risk of later dysglycaemia, and six amino acids helped predict who would develop it.
In 1,095 high-risk abdominal-surgery patients, targeting each person's own cardiac index during the operation left the rate of major complications essentially unchanged — 44.3% versus 46.9%.
Among 84 women on aromatase inhibitors, CO2 laser did no better than a fake laser for sexual function at 12 months. Both groups improved — on moisturisers and vibrators given to everyone.
In a 17-person phase 2a trial, once-weekly inhaled SPL84 lifted lung function in up to 70% of treated patients with the 3849+10 kb C→T mutation — a first reported clinical signal for an RNA-targeted inhaled therapy.
In 7,186 Korean adults followed up to 20 years, people flagged by fasting glucose, glucose tolerance and HbA1c all at once had a 15.3-fold higher risk of type 2 diabetes than normal controls.
LOTIS-9 tested loncastuximab tesirine plus rituximab in unfit and frail older adults with untreated DLBCL. Complete responses reached 53% and 42%, but severe side effects, including 11 deaths, ended the trial early.
Among 287 people with REM sleep behaviour disorder followed about four years, 15.7% developed a synucleinopathy. Higher coffee intake was linked to a lower risk of progression.
SLOWH, a 102-patient randomised trial, compared cutting flow first, oxygen first, or both at once when weaning critically ill adults off high-flow nasal cannula. Success rates of 94%, 81% and 77% did not differ.
A 60-woman phase 2A trial found the dual PPAR agonist reduced liver fat by nearly 15 percentage points more than placebo over 24 weeks — an early, small signal in a group usually left out of fatty-liver drug trials.
An Israeli records study of 181,000 adults found people now diagnosed are older and sicker, but start with better glucose and cholesterol, and far more leave the clinic on SGLT2 or GLP-1 drugs.
Hovilpri (pritelivir), a helicase-primase inhibitor, was approved on 9 October for immunocompromised adults whose herpes lesions resist aciclovir. In its trial, 63% healed by day 28 against 34% on comparator therapy.
An observational study of 8,127 UK women on GLP-1 drugs, almost all tirzepatide, reported 16.1 kg average loss at six months and 91.4% retention. There was no control arm.
On 14 October the FDA extended nogapendekin alfa inbakicept-pmln, with BCG, to BCG-unresponsive papillary-only disease - a first for that group - without a new trial, by extrapolating from its carcinoma-in-situ data.
A detailed safety analysis of the 12,254-patient OCEANIC-STROKE trial found no significant rise in major bleeding with the factor XI blocker, though lower gastrointestinal bleeding was more frequent.
A prespecified analysis of 227,502 veterans who contacted the Veterans Crisis Line found suicide mortality of 0.29% among caring-letter recipients versus 0.27% in historical controls — no measurable difference.
Teva's subcutaneous depot is built to avoid the post-injection sedation that hobbled the first olanzapine shot. It cleared the FDA on 8 October; in the phase 3 SOLARIS trial it beat placebo on symptoms at eight weeks.
In the phase 3 VERIFY trial, 77% of patients on the hepcidin-mimic drug avoided phlebotomy over weeks 20–32 versus 33% on placebo, and far more kept their haematocrit under control.
In 4,299 people with type 1 diabetes and 17,196 matched controls, the death rate was 131 vs 35 per 100,000 person-years. The excess risk was far larger in women, though absolute mortality was higher in men.
The pill joins trastuzumab and pertuzumab as maintenance after induction. In the 654-patient HER2CLIMB-05 trial it stretched median progression-free survival to 24.9 months from 16.3, a hazard ratio of 0.64.
The phase 3 RT CHARM trial found a three-week course of radiation after mastectomy was no worse than the standard five-week course for reconstruction complications, at 12.3% versus 10.2%.
Rhapsido becomes the first drug labelled for the itchy welts raised by scratching or pressure. In the RemIND trial, 29.3% on the pill cleared the provocation test at week 12 versus 14.0% on placebo.
In 204 patients already on standard therapy, pressing a seed on one ear point three times daily left 56.9% clear or almost clear at 8 weeks versus 35.3% with a sham point — a single-centre result needing replication.
Among 7,579 pregnancies in people with migraine, anti-CGRP antibody use early in pregnancy carried a 42% higher adjusted risk of spontaneous abortion; propranolol showed no increase. The data are observational.
The phase 2 ROXAMI trial gave the oral HIF stabiliser roxadustat to 158 STEMI patients after stenting. Infarct size at 30 days was no smaller than with standard care. Later remodelling findings were exploratory.
RINGSIDE phase 2 tested three doses of oral varegacestat in 42 adults with progressing desmoid tumours. The lowest daily dose gave the deepest shrinkage and was carried into phase 3. No comparator arm.
In a 28-patient single-arm phase 2 study, disitamab vedotin with tislelizumab produced a complete response in 73% of evaluable HER2-positive bladder cancers that could not be resected. There was no comparator.
In a 134-patient phase 3 crossover trial, deucrictibant — the first oral bradykinin B2 receptor blocker — brought symptom relief in a median 1.28 hours, against more than 12 hours on placebo.
A single-centre study used continuous glucose monitoring to fine-tune insulin in people fed intravenously overnight. Time-in-range and weight improved — but with 12 patients and no control group, it is proof of concept.
ESO-T01 builds cancer-killing T cells inside the body, skipping the cell harvest and chemo prep normal CAR-T needs. All four responded — but the cells faded, and median progression-free survival was 4 months.
A 37-hospital registry tracked 17,602 adults whose hearts stopped while admitted. CPR usually started within a minute, yet only 9.1% survived to discharge — and after-care lagged far behind the initial response.
In a 348-patient trial, patients in sustained low disease activity who stepped down their biologic kept it almost as often as those who stayed on full dose over 24 weeks — but some measures still favoured continuing.
Across 27 trials and 88,830 people, each 10-mmHg drop in systolic pressure cut cardiovascular events whether or not the kidneys were impaired — while aggressive lowering nudged up short-term markers of kidney decline.
A phase 1/2 trial gave mosunetuzumab plus polatuzumab to 101 older, unfit or frail people with untreated large B-cell lymphoma. The end-of-treatment response rate was 61.4%, with a complete response in 56.4%.
A single-arm phase 2 trial added glofitamab to pola-R-CHP in 41 people with newly diagnosed B-cell lymphoma. The best complete-response rate was 95%, cytokine release stayed grade 1, and no neurotoxicity was reported.
A randomised trial enrolled 3,259 underserved people referred for lung cancer screening. Adding free medication to standard advice did not raise quit rates; adding financial incentives roughly doubled them — to 8.8%.
A Toronto cohort reports that an eight-day antiviral protocol prevented or cleared hepatitis C in all 116 recipients of organs from infected donors, with survival matching recipients of uninfected organs.
In the Nordic SWEDEGRAFT trial, the no-touch vein-harvesting technique left the rate of death, heart attack, or repeat procedures at 19.8% versus 20.4% through seven years — a difference indistinguishable from chance.
In the industry-funded evERA trial, giredestrant plus everolimus delayed progression of ER-positive breast cancer — but the clearest benefit was in ESR1-mutated tumours, and the endpoint was a surrogate, not survival.
Thirteen years on, the independent DiAPREV-IT trial still shows no overall effect from GAD-alum. A 27-child genetic subgroup saw onset delayed — but the other subgroup got worse.
The UV-free TransVitD patch raised vitamin D in animals and lab-grown skin. In a randomised trial of 108 volunteers it was safe but did not lift blood levels beyond what a small oral dose would.
AbbVie's once-daily pill cleared the FDA on 25 September as a new molecular entity. Across three phase 3 TEMPO trials it beat placebo in early Parkinson's and as an add-on to levodopa.
In the phase 3 SYNCHRONIZE-2 trial, the glucagon/GLP-1 dual agonist beat placebo on weight over 76 weeks. The effect was solid but smaller than the class leaders manage, and the maker funded it.
Two phase 3 trials put the oral drug safiglipron ahead of placebo and non-inferior to dapagliflozin on HbA1c. Both ran only in China, were maker-funded, and showed dose-dependent gut side effects.
A post hoc analysis of the BAMBINI trial asked whether losing too much weight could backfire on fertility in PCOS. It did not: every degree of weight loss was linked to a better chance of ovulating.
There has been no reliable way to prevent pre-eclampsia at term. PREVENT-PE screened over 8,000 women late in pregnancy and offered earlier birth to those at highest risk — and pre-eclampsia fell by nearly a third.
Injecting one sperm into each egg was meant for severe male-factor cases, yet clinics now use it widely. Pooling six randomised trials found no live-birth advantage over standard IVF when sperm is not the problem.
Falling cervical cancer rates after HPV vaccination are well known. A 2026 analysis of mortality data goes further: among women vaccinated at 12–13 with ~90% coverage, no deaths were recorded against about 23 expected.
Computer-aided detection lifts polyp pickup in ordinary screening. In 757 patients having surveillance for an inherited cancer syndrome, a randomised trial could not show the same gain.
In the phase 3 UKALL14 trial, one cycle of the T-cell drug nelarabine after induction was well tolerated but left event-free survival essentially unchanged in adults aged 25 to 65.
In a 200-patient prospective validation, a DNA-methylation assay reached an AUC of 0.91 and, by one analysis, could have averted about 55% of unnecessary biopsies without missing significant cancers.
A randomised Asian trial in 130 patients found no efficacy gap between the two drug regimens for active lupus nephritis, but serious infections and all three deaths fell in the mycophenolate group.
ROAM/EORTC-1308, an independent phase 3 trial, randomised 157 patients after complete brain-tumour removal; adjuvant radiotherapy improved five-year disease-free survival, but the benefit's confidence interval was wide.
RESOLVE randomised 880 treatment-naive, non-cirrhotic patients to a shorter sofosbuvir–velpatasvir course; cure rates were non-inferior to the 12-week standard, with implications for the cost of elimination programmes.
The PLUSS trial put a steroid directly into the lungs of 1,059 infants born before 28 weeks. Survival free of chronic lung disease barely differed from surfactant alone.
A single-centre, placebo-controlled trial found targeted onabotulinumtoxinA injections cut dystonia-related foot pain without harming movement. The effect was large, but the trial randomised only 33 people.
Final results of the phase 3 IMpassion050 trial show adding the immunotherapy atezolizumab to standard HER2-targeted treatment did not improve event-free or disease-free survival.
In Scottish hospital data, RSV was recorded about 2.3 times as often as human metapneumovirus, but patients admitted with either virus were similarly ill — and the analysis was funded by a maker of RSV products.
The phase 3 CLL6 RESIDUUM trial extended progression-free survival by about 22 months in patients left with residual disease, but overall survival did not differ and the drug caused more infections.
The CENTERSTONE trial found a single dose lowered lab-confirmed spread to household contacts by about a third, but spread that made contacts ill was not significantly cut, and resistant virus emerged in some patients.
In the Scandinavian phase 3 ASAC trial, daily aspirin failed to improve disease-free survival after treatment of colorectal cancer liver metastases — and overall survival was worse on the drug.
ACHIEVE-4 found the non-peptide GLP-1 pill non-inferior to insulin glargine for major cardiac events over two years, with less severe hypoglycaemia but far more gastrointestinal upset. Lilly funded it.
Ketamine cuts suicidal thinking fast but briefly. A 50-person trial gave low-dose buprenorphine afterward and saw the effect hold — an early, single-centre result in a high-risk group.
A population-linked Australian cohort followed children to school entry after antenatal metformin. The adjusted relative risk of developmental vulnerability was 0.97 — no different from unexposed children.
Merck's sotatercept gained an FDA efficacy supplement on 21 September. In the phase 3 ZENITH trial, a composite of death, transplant or hospitalisation hit 17.4% on the drug versus 54.7% on placebo.
The FDA approved PTC Therapeutics' sepiapterin in July 2025. In the phase 3 APHENITY trial, responders saw a 63% fall in blood phenylalanine over six weeks against roughly no change on placebo.
In the phase 3b STRIDE trial, people with peripheral artery disease and type 2 diabetes walked 13% farther at 52 weeks than on placebo (treatment ratio 1.13; p=0.0004). The gain is modest; Novo Nordisk funded it.
A randomised trial at eight South Korean hospitals found pulse methylprednisolone no better than a non-pulse regimen for surviving an acute exacerbation of idiopathic pulmonary fibrosis.
A Swiss investigator-led trial tested whether isolating the back wall of the left atrium on top of pulsed-field pulmonary vein isolation cuts arrhythmia recurrence. The primary answer was no.
In the phase 2 KRAKEN trial, muvalaplin lowered lipoprotein(a) by 47.6% to 85.8% over 12 weeks on an intact-particle assay. Eli Lilly funded it, and the trial was not built to measure heart attacks or strokes.
In the GSK-funded phase 3 MATINEE trial, the anti-IL-5 antibody lowered moderate or severe exacerbations from 1.01 to 0.80 a year — but symptom and quality-of-life endpoints showed no significant benefit.
In a phase 2 trial in people whose hidradenitis suppurativa had already failed anti-TNF drugs, two lutikizumab doses beat placebo at 16 weeks. A third did not, and the placebo response was high.
The oral histone deacetylase inhibitor cleared the FDA in March 2024. In the phase 3 EPIDYS trial, boys on givinostat still lost function over 72 weeks — just less of it than those on placebo.
A single-surgeon randomised trial of 180 knees found small but statistically supported gains for robot-assisted functional alignment over conventional mechanical alignment at two years.
In EMPACT-MI, the SGLT2 inhibitor missed its primary endpoint: 8.2% of patients had a heart-failure hospitalisation or died versus 9.1% on placebo (hazard ratio 0.90; p=0.21). Boehringer and Lilly funded it.
Emcitate cleared the FDA on 28 September as a new molecular entity. In an open-label trial of 45 patients, the drug lowered the high serum T3 that drives MCT8 deficiency by about two-thirds.
Bristol Myers Squibb's mavacamten gained an FDA efficacy supplement on 30 September. In the pivotal EXPLORER-HCM trial, 37% on the drug met the primary endpoint versus 17% on placebo.
AMPLIFIED enriched for early rheumatoid arthritis patients thought to respond best to abatacept, then compared it head-to-head with adalimumab. At week 24 the two drugs were indistinguishable.
Rezzayo's once-weekly echinocandin can now be used in adolescents with candidaemia who have few other options. The expansion rests on adult data and modelling, not on studies in children.
BeiGene's PD-1 antibody, added to the HER2 drug zanidatamab and chemotherapy, lifted median overall survival to 26.4 months from 19.2 in the HERIZON-GEA-01 trial. The gain concentrated in the strongest HER2-expressers.
In the publicly funded SWOG S1600 trial, specialised immunonutrition before and after radical cystectomy left 30-day complication rates essentially unchanged: 62% versus 58% on a standard drink.
A government-funded test-negative study put effectiveness at 86% against emergency visits and 88% against intensive care, though the smallest subgroups carried wide confidence intervals.
A test-negative study across seven paediatric hospitals in Ontario and Quebec, run after a publicly funded rollout, estimated 78% effectiveness against laboratory-confirmed RSV and 97% against intensive-care admission.
The academic MATRix/IELSG43 trial found autologous transplant lifted 3-year progression-free survival to 78% from 51%, but at the cost of more toxicity and more treatment-related deaths.
A phase 1 trial in 288 Chinese children found the experimental injectable vaccine well tolerated and able to raise antibodies. It measured immune response, not whether it prevents disease.
A European registry compared 52 transplanted patients with 79 untreated ones over up to 25 years. The benefit was clearest when transplant came before symptoms, and it did not stop progression entirely.
A Shionogi-funded randomised trial found that giving household contacts a five-day course dropped the rate of symptomatic Covid from 9.0% to 2.9%, with no severe cases in either group.
The publicly funded E4512 trial found two years of crizotinib after surgery did not prolong disease-free survival against observation, with a hazard ratio of 1.08 and no safety upside.
In the investigator-led Danish DALIAH trial, pegylated interferon-alfa and hydroxyurea produced similar molecular responses by intention-to-treat, but far more patients stopped interferon.
A cluster-randomised trial in nearly 2,000 US nursing homes found fewer confirmed influenza outbreaks with a recombinant vaccine in a moderate flu season, but no difference in a near-flu-free one.
A small crossover trial found 5 mg of melatonin worsened glucose handling and cut early insulin secretion in people carrying the MTNR1B risk variant, but not in non-carriers.
In the LOSE-AF trial, an eight-month low-calorie programme cut weight by 9.7% in older adults with AF. It did not change their symptoms, their AF burden, or their need for further rhythm treatment.
Cleared on 10 July under NDA 218579, the Provepharm agent fluoresces in near-infrared light to map vessels, perfusion and lymph nodes during surgery. Efficacy rests on studies of an earlier formulation.
Approved on 24 June under NDA 220436, the Avyxa Holdings product is a ready-to-infuse form of the NK-1 blocker fosaprepitant, cleared on studies of an earlier intravenous version of the drug.
A Spanish registry followed 166 patients with treatment-resistant epileptic encephalopathies for a year. Median seizure frequency fell 68.8%, though the design cannot match a placebo-controlled trial.
A pooled analysis of four trials found depemokimab roughly halved exacerbations, yet it did not significantly improve asthma control or reach the threshold for a meaningful quality-of-life gain.
Against 304 carbapenem-resistant A. baumannii isolates from six countries, the experimental drug zosurabalpin kept low MICs — including against metallo-beta-lactamase producers. This is laboratory data, not a cure.
There is still no licensed Lyme vaccine. In a phase 2 trial of VLA15, a second yearly booster revived antibody levels against all six OspA serotypes, with more sore arms but no new safety signals.
A bird-flu virus from British Columbia poultry carried the H275Y mutation that blunts Tamiflu and peramivir. In the lab it stayed vulnerable to zanamivir and baloxavir — and was less virulent in mice.
Gilead's phase 3 trial in 539 patients was terminated after the CD47 antibody failed to improve remission or survival and caused more fatal adverse events than azacitidine alone.
A US analysis of the 2025-2026 vaccines targeting the LP.8.1 lineage found both an mRNA-1283 and a BNT162b2 shot reduced COVID hospitalisation in older adults, with the strongest effect in those aged 75 and over.
Ruxolitinib cream beat a placebo cream for cutaneous lichen planus over 16 weeks, but the phase 2 trial randomised only 64 patients and was funded by the drug's maker.
Regeneron's activin A antibody, brand name Pasatru, cleared the FDA on 19 August. In the pivotal 63-patient trial, new abnormal-bone lesions fell by 90% or more against placebo over 56 weeks.
The Scholar Rock antibody cleared the FDA on 11 September. In the phase 3 SAPPHIRE trial, apitegromab plus standard therapy beat placebo by 1.8 points on a motor-function scale at 12 months.
The final analysis of Roche's phase 3 trial found the anti-TIGIT antibody did not significantly extend progression-free or overall survival when added to atezolizumab in 521 patients.
Two-year blinded data and open-label follow-up from the ELATIVE trial show the drug kept improving liver blood tests in primary biliary cholangitis — but the endpoint is still a surrogate, and the trial is industry-run.
In the company-run CONDOR trial, brolucizumab injections outperformed panretinal laser for proliferative diabetic retinopathy over 54 weeks — while intraocular inflammation was far more common in the drug arm.
A meta-analysis of 10 randomised trials found ultra-processed diets raised weight and eating rate, yet the effect on how much people ate mostly disappeared when diets were not more energy-dense.
LOGICAL randomised 1,840 unresponsive adults in Australia, New Zealand and Ireland to conservative or liberal oxygen in intensive care. Favourable outcome at 180 days was 38.2% against 39.7%.
In the phase 3 INDIGO trial, weekly obexelimab roughly halved the risk of a flare in this rare fibroinflammatory disease and spared patients steroids — a positive result in a condition with no approved drug.
Heartburn is one of the most common complaints in pregnancy. Diet and posture changes come first; a Cochrane review found antacid-type medicines relieve it, but the trial evidence is thin and drug choice needs care.
In 410 German women, 68% who had liposuction met the pain-reduction target at 12 months versus 8% on conservative therapy. Serious adverse events were higher after surgery.
Sleeping apart is increasingly common and can genuinely cut disturbance. But the lab evidence is double-edged: sharing a bed measures as slightly worse sleep yet feels better, and may even boost REM.
The VITAL trial randomised 2,508 patients aged 50 and older to propofol-based or inhaled anaesthesia and found no difference in days alive and at home at 30 days, or in death, delirium or major complications.
The TRACK trial was stopped early for futility. The blood thinner failed to reduce a composite of cardiovascular events, while major bleeding rose by half. Bayer, which makes the drug, was a listed collaborator.
In the phase 3 TenCRAOS trial, intravenous tenecteplase given within 4.5 hours did no better than aspirin at recovering sight, and carried more bleeding — including one fatal brain haemorrhage.
The NIH-funded STArT trial in children and young adults was halted for futility: time to crisis resolution was 60.8 hours with arginine versus 65.8 with placebo, well within the range of chance.
SOLARIS, a publicly funded phase 3 trial, tested vitamin D3 added to chemotherapy after a promising phase 2 signal. Progression-free survival was 11.8 versus 10.3 months — not a significant difference.
A double-blind Danish trial gave the drug or placebo during resuscitation at 21 hospitals. Restored circulation occurred in 39% versus 37% — no meaningful difference — and bicarbonate raised blood alkalosis and sodium.
In the SNAP platform trial, cefazolin was non-inferior to flucloxacillin or cloxacillin for 90-day survival in methicillin-susceptible S. aureus bacteraemia, and caused notably less acute kidney injury.
In the phase 3 SWOG/NRG S1914 trial, adding atezolizumab to stereotactic radiotherapy for high-risk, inoperable early lung cancer left 2-year survival at 82% in both groups and caused more serious side effects.
In the industry-funded ADVANCE OUTCOMES trial, the once-daily prostacyclin-pathway drug more than halved the risk of a first worsening event, but drove far more treatment discontinuations for side-effects.
The PROPOSITIS trial put babies on high-flow oxygen face-down or on their backs. Escalation of care was 15% versus 21% — a difference that did not reach significance, and the authors call the study inconclusive.
In GASTRIC-PICU, 4,700 ventilated children were randomised to routine gastric residual checks or none. Dropping the checks was non-inferior for survival and ventilator-free days, and improved nutrition.
Ceperognastat, an oral OGA inhibitor, showed no benefit on the primary cognitive endpoint at 100 weeks. The higher dose progressed 32% faster than placebo and had more serious adverse events.
VICTORY randomised 238 adults with severe burns to intravenous vitamin C or placebo. It was stopped early: 28-day mortality was 15.0% versus 7.6%, and the trial crossed a prespecified harm threshold.
An overactive thyroid speeds the body up; an underactive one slows it down. But no single symptom is reliable — in one large screening study, individual thyroid symptoms were poor at flagging who actually had a problem.
REPLENISH randomised 381 patients with relapsed polymyalgia rheumatica. Sustained remission at 52 weeks reached about 41% on secukinumab versus 20.4% on placebo. Novartis funded the trial.
In the 1,658-person PUSH trial, a behavioural programme with financial incentives raised urine volume but left symptomatic stone recurrences unchanged over two years — 19% against 20% with usual care.
Rejoyn, the first prescription digital therapeutic cleared for major depression, beat a sham app on a backup analysis. Its pre-specified primary endpoint fell just short of significance.
Wrist trackers infer light, deep and REM sleep from movement and pulse. Two validation studies find they track total sleep passably but each misjudges the stage breakdown its own way.
A deep-learning model reads the pancreas on non-contrast CT taken for other reasons. It reached very high accuracy in large tests — none of them a prospective screening trial.
Long static stretches before training briefly weaken strength and power, and stretching does not prevent soreness or reliably cut injury. Save static stretching for after, or for flexibility itself.
The muscle-building literature converges on roughly 1.6 grams of protein per kilogram of bodyweight a day, with gains flattening above that — a target well clear of the deficiency floor most official figures quote.
No. When sets are pushed close to failure, light and heavy weights build muscle about equally. The one thing heavier loads reliably win is maximal strength.
A warm bedroom measurably degrades sleep, and the best-studied comfortable band sits at roughly 20–25°C. The effect is real but personal, and heat matters more than most people assume.
Knowing you are dreaming and sometimes steering it is real and surprisingly common, and it can be trained. But deliberately inducing it may carry a mental-health cost for some people.
The viral drink pairs tart cherry juice with a magnesium supplement. Both have some human trial data for sleep, but it is thin, small and low-quality — far short of what the trend implies.
The viral countdown says no caffeine 10 hours before bed, no food at 3, no work at 2, no screens at 1. The caffeine and food steps have real evidence behind them; the rest is thinner.
Yes, within limits. Short sleep is linked to more colds and weaker vaccine responses, but the strongest effects turn up when sleep is measured objectively, not from what people report.
When researchers tested people with insomnia, those told to picture an engaging scene fell asleep faster. A vaguer instruction to just distract yourself, the counting-sheep approach, did not.
For most healthy adults the measured difference is small. But side-sleeping has real evidence in three specific situations: nocturnal reflux, obstructive sleep apnoea and late pregnancy.
In the phase 2 Vibrance-1 trial, alixorexton lifted mean sleep latency from about 2 minutes on placebo to 24 or more on the drug. The six-week study was funded by the manufacturer.
In the SOLARIO trial, patients who got local antibiotics at surgery did no worse on a short systemic course than a long one, and reported far fewer side effects. The comparison was independently funded.
In a single-arm trial, children with vanishing white matter given guanabenz kept walking longer than matched historical controls. The design was uncontrolled and hallucinations were common early on.
In the publicly funded EPoS II trial, waiting five years before the next colonoscopy was no worse than the recommended three at an interim look, with near-identical cancer rates. Ten-year data are still to come.
Ginger's strongest evidence is unglamorous: it eases nausea in pregnancy and during chemotherapy, and modestly relieves osteoarthritis pain. The trials are small and the quality is moderate at best.
Garlic supplements modestly lower blood pressure in hypertensive people, and may nudge cholesterol down a little. The cold-prevention evidence rests on a single trial, and no study shows garlic prevents heart attacks.
Beetroot juice really does lower blood pressure — the effect is one of the better-documented in food science, driven by dietary nitrate. But most trials are short and small, and no study shows it prevents heart attacks.
For people without coeliac disease, a large cohort found gluten intake was not linked to heart disease — and cutting it often means fewer whole grains, the foods tied to lower cardiovascular and mortality risk.
"Superfood" is a marketing word, not a scientific one. Blueberries carry real evidence for the heart and, tentatively, the ageing brain — but most of it is observational or short-term markers, not hard outcomes.
The largest synthesis of experimental sleep research finds that shorter, broken or lost sleep flattens positive emotion and ramps up anxiety — and trials that fix sleep improve mental health in turn.
Across 154 studies, activities that lower arousal — slow breathing, meditation — reduced anger and aggression. Venting-style activities that raise it, like hitting a bag or going for a run, did not.
At high doses caffeine reliably provokes anxiety and can trigger panic attacks in vulnerable people. The effect is dose-dependent, habitual drinkers differ, and disrupted sleep is part of the story.
Slow breathing does shift the body toward calm, but the popular 4-7-8 count has almost no direct trial evidence, and the breathwork that has been tested in a large study is a different pattern.
Repeating 'I'm a lovable person' left people with low self-esteem feeling worse in controlled experiments. A different technique — writing about your core values — has stronger evidence behind it.
A 40-person Harvard trial aimed accelerated magnetic stimulation using each patient's own connectivity scan. Depression scores fell further than with standard scalp measurement, though the trial was small.
In the French GETUG AFU 18 trial an 80 Gy dose beat the standard 70 Gy on 10-year progression-free survival (83.6% vs 72.2%), but the advantage at the prespecified 5-year mark was far smaller.
A short walk after eating blunts the post-meal blood-sugar spike. Trials in people with type 2 diabetes and in healthy adults agree, and light walking beats standing, which beats sitting still.
Sea moss is sold as a 92-mineral cure-all, but no human trial shows it delivers those benefits — and because seaweed's iodine content is wildly variable, the documented risk falls on the thyroid.
Two blinded randomised trials found magnetic wrist straps and copper bracelets worked no better than dummy versions for arthritis pain. The reported relief looks like a placebo effect.
US regulators class MSG as generally recognised as safe, and when the symptoms are tested under blinded conditions they largely disappear. The clearest signal is a nocebo effect, not the additive.
The popular 21-day rule has no basis in the habit-formation research. In the one real-world study, the time to reach automatic behaviour ranged from 18 to 254 days — and plateaued on average near 66.
Wellness marketing says reconnecting to the Earth's electrons lowers cortisol, inflammation and pain. The human studies are small, mostly unblinded, and largely produced by the idea's own advocates.
Greens powders are sold as insurance against a poor diet. There are almost no independent trials of the products themselves — and the strong evidence is for eating vegetables, not drinking them.
Loading up on dietary fibre is the rare viral trend with strong data behind it: high-fibre eaters have markedly lower mortality. But the evidence is for whole foods, not powders, and tracks a habit, not a one-day stunt.
No. Sweat is how the body sheds heat, not fat. The weight lost in a hot workout or a sauna is water, and it comes back the moment you rehydrate.
Two meta-analyses of 104 trials found music lowered both felt stress and physical markers like heart rate. The effect is consistent and moderate — larger for how stressed people feel than for blood pressure.
Early studies made elderberry look promising for colds, and sales topped $100 million. But the trials are small, and the most rigorous one — a randomised flu trial in emergency patients — found no benefit at all.
Echinacea is a pharmacy staple every winter. But a Cochrane review of 24 trials found no reliable treatment benefit, and the largest trial shaved barely half a day off a cold — a difference too small to be sure was real.
No trial shows chicken soup cures or shortens a cold. But two small, decades-old studies found it clears nasal mucus faster than plain hot water and calms one inflammatory cell in the lab — a case for comfort, not cure.
In a driving study, 200 mg of caffeine followed by a nap under 15 minutes cut simulator incidents to 9% of placebo levels, against 34% for caffeine alone. The order is the point.
Standing up every half hour is common desk advice. A meta-analysis of seven trials found brief standing breaks trim post-meal glucose a little, but short light-walking breaks cut both glucose and insulin far more.
Barely, and some carry real risk. Caffeine has a small, measurable effect; the other headline 'thermogenic' ingredients mostly don't, and high-dose green tea extract has caused liver injury.
TikTok says a castor oil pack on the abdomen detoxes the liver, balances hormones and melts bloating. The oil's only proven action is as a laxative when swallowed — not soaked in through skin.
You cannot turn a healthy immune system up like a dial, and nothing on the supplement shelf has been shown to. What the trials do show is narrower: fix a sleep deficit and you catch fewer colds.
When adults see a doctor for new fatigue, fewer than one in ten turn out to have clear physical disease. The common, treatable and often-missed exception is iron deficiency, which drains energy before it causes anaemia.
Nail changes can hint at systemic disease — clubbing, spoon-shaped nails, splinter haemorrhages. But the everyday worries, like lengthwise ridges and little white marks, are usually harmless.
Two Cochrane reviews put numbers on it: oral terbinafine and azoles cure far more toenail infections than placebo, while newer topical solutions work but cure a minority — over nearly a year of daily use.
TEMPLE, an AbbVie-funded phase 3b trial, is the first direct test of the CGRP blocker atogepant against topiramate — a long-used preventive many patients cannot tolerate.
SINGLE-AF randomised 1,803 South Koreans with borderline stroke risk to a direct oral anticoagulant or nothing. The drug lowered a composite of stroke, bleeding and death at two years, from 1.5% to 0.5%.
The flaky, red patches on scalp, brows and nose folds are an inflammatory reaction, not poor hygiene. Ketoconazole cream cut treatment failure 31% against placebo, and short steroid courses tripled clearance.
In PHOENYCS GO, dapirolizumab pegol lifted the share of lupus patients reaching a composite response at 48 weeks to 50% from 35% on placebo — a real but modest 14.6-point gain.
The brown facial patches come from overactive pigment cells in sun-aged skin. Triple-combination cream beats hydroquinone alone (risk ratio 1.58) and tranexamic acid helps, but relapse is the rule.
The bumps are plugged hair follicles, not dirt or a deficiency. Keratolytics help modestly and temporarily: lactic acid cut lesions 66% and salicylic acid 52% over 12 weeks, but they return when you stop.
Open-angle glaucoma steals side vision so slowly that half of people who have it don't know. There is no way to prevent it — but a placebo-controlled trial showed pressure-lowering drops preserve vision.
In heart patients, randomised trials link influenza vaccination to fewer cardiovascular events and deaths. The effect is clearest in the highest-risk patients, and the largest trial stopped early.
Floaters are usually ageing changes in the eye's gel. But among people who suddenly develop floaters and flashes, about 14% turn out to have a retinal tear — which can lead to permanent vision loss if left.
Eye exercises won't sharpen blurry sight or cure nearsightedness — glasses and surgery do that. But one focusing problem, convergence insufficiency, does respond: an office-based programme helped 73% in a trial.
When fingers and toes turn white then blue in the cold, it is often Raynaud's phenomenon. A Cochrane review finds the standard drugs — calcium channel blockers — cut attacks only modestly.
Chronic hives are mast-cell driven and usually have no external trigger. Antihistamines clear some cases; at 12 weeks omalizumab cut a weekly itch score by 9.8 points at 300 mg, against 5.1 on placebo.
In the investigator-led CAVIAR trial, adding the PCSK9 inhibitor alirocumab to a statin after heart transplant more than halved LDL cholesterol but did not slow coronary plaque growth at one year.
By age 80 most people have a cataract or have had one removed. You can lower some risks, but the antioxidant vitamins tested in a 4,629-person trial did not slow them, and surgery is the only cure.
Carpal tunnel syndrome is median-nerve compression at the wrist. Cochrane reviews find steroid injections clearly help for about a month, while surgery beats non-surgical care at three and six months.
An 840-child US trial gave the antibiotic to toddlers with moderate-to-severe wheezing in the emergency department. Symptom scores were no better than placebo, and the study was stopped for futility.
The Essilor-designed HAL lenses cut two-year myopia progression by 71% versus ordinary glasses in 159 American children. The company employs the study's authors, and the result backs the device's US clearance.
A four-image bitewing set delivers about 5 microsieverts, a panoramic scan 14 to 24. A cone-beam CT can be tens of times higher. The dose is small, but technique and how often you scan drive it more than anything.
That heavy, foggy feeling on waking is often sleep inertia — a normal, temporary state, not a sign you slept badly. It bites hardest when you wake from deep sleep or during the biological night.
A large public randomised trial found reading a book in bed nudged sleep quality up. But the format matters: paper helps, while a glowing screen can quietly work against you.
The large trials built to confirm vitamin E's promise came back null, and a meta-analysis tied 400 IU a day or more to a small rise in all-cause mortality.
In deficient populations, vitamin A supplements cut child deaths by 12% — among the best-evidenced global-health interventions. In the well-nourished, added vitamin A does no good and can do harm.
Pooling 58 randomised trials, about 3.5g a day of oat beta-glucan lowered LDL cholesterol by 0.19 mmol/L. A separate meta-analysis of 28 trials found 0.25 mmol/L. Small per person, but consistent.
Cohort data link green tea drinking to lower cardiovascular death, but trials show only surrogate changes and concentrated extracts have caused liver injury at everyday catechin doses.
Trials can show cinnamon nudging fasting glucose down, but the effect is inconsistent, leaves long-term control (HbA1c) untouched, and cheap cassia cinnamon carries a coumarin safety flag.
Bigger weekly doses of nature track with better wellbeing, structured outdoor programmes ease depression and anxiety in trials, and a single walk can quiet the overthinking that feeds low mood.
An analysis of 50 top-selling 'T booster' products found only 24.8% contained an ingredient with data showing it raises testosterone — and 10.1% contained something shown to lower it. Two herbs are partial exceptions.
Topical vitamin C is a real antioxidant that helps skin build collagen. Split-face studies show measurable smoothing, but a systematic review found only seven usable trials, almost all mixing it with other actives.
Surveys have flagged lead, cadmium and arsenic in some powders, but a risk assessment of those same numbers found typical intakes stayed below the thresholds used to judge harm.
Omega-3 supplements are widely recommended for dry eye, but the largest randomised trial found them no better than an olive-oil placebo. A Cochrane review leaves the case uncertain at best.
Short courses look well tolerated, but trials rarely run past a few weeks, so long-term safety is untested. Two clearer problems: variable supplement content, and a surge in children's accidental ingestions.
Percussive devices reliably loosen muscles and add short-term flexibility, but pooled trials show no clear gain for maximal-strength recovery or next-day soreness — and they can dent explosive output before training.
Writing about your thoughts and feelings has a real but small average effect across 146 trials; a web-based journaling study eased anxiety in medical patients. Useful, not a cure.
Rubbing ice on your face constricts vessels for a moment, but a controlled cold study found lower skin hydration and more redness, not firmer skin — and prolonged cold makes vessels reopen.
Products promising to 'balance your hormones' lean on botanicals like maca, black cohosh and phytoestrogens, and on the hormone DHEA. When those ingredients are put in controlled trials, the evidence is limited or null.
Exercising before breakfast shifts which fuel your body uses during the session, but pooled trials find no meaningful edge for weight or body-fat loss over the same workout done fed.
Reading in poor light makes eyes feel tired, but there is no evidence it causes lasting damage. What really shapes eyesight is near-work load and time in bright daylight — and it acts in childhood.
A JAMA Dermatology review found the best-evidenced products — Viviscal, Nutrafol and a few others — but flagged weak studies and industry funding. For people who eat normally, the case is thin.
For most people eating normally, added electrolytes do little, and plain water rehydrates fine for ordinary exercise. The clearest endurance danger is drinking too much — and the proven use is illness, not the gym.
Positional flat head affects nearly half of two-month-olds and is usually mild. In the one randomised trial, moulding helmets matched the natural course — and every parent reported a side effect.
Up to a third of children get the label, but a review of 145 studies shows doctors do not agree what growing pains are — not even that they involve the legs. Here is what the evidence supports, and the warning signs.
A Cochrane review found no evidence that antibiotics ease the pain of an inflamed tooth nerve. The best trial evidence points to ibuprofen, with paracetamol added — but only a dentist fixes the cause.
There is no single number. Normal depends on which test is used and whether you have fasted — and the cut-offs that define prediabetes and diabetes are lines drawn on a continuous scale.
The occasional held bladder is not going to burst or poison you. The real concern is habit: routinely ignoring the urge, or being unable to empty at all, which is a medical emergency.
Stifling a sneeze is usually harmless, but doctors have documented rare, serious injuries — a torn throat and a fractured voice box — when the trapped pressure has nowhere to escape.
About 7.5% of sexually active women in Britain reported pain lasting three months or more, a national survey found. The usual causes — dryness, vulval pain, infection, endometriosis — are treatable.
Popular extras like embryo genetic testing and endometrial scratching did not raise live-birth rates in their biggest randomised trials, and the UK regulator warns most patients need none of them.
An umbrella review of 21 meta-analyses found caffeine helps endurance, strength, power and sprinting. The effect is real but modest, and the useful dose is smaller than many gym pre-workouts pack in.
A short nap does not wreck most people's night sleep, and can help offset sleep debt. The evidence that gives pause is about long naps: naps of 60 minutes or more track with worse cardiovascular outcomes.
When you eat may shape how you sleep, but the science is young. The clearest signal is that a heavy meal close to bedtime disrupts sleep, while simply shrinking your eating window neither reliably helps nor harms it.
The 2024 American Academy of Sleep Medicine guideline strongly backs intravenous iron and gabapentinoids, and now suggests against the dopamine agonists that were first-line for two decades.
About a quarter of people sneeze on stepping into bright light. It runs in families, has been tied to specific gene variants, and looks like visual signals spilling into the sneeze circuit.
In the 142,250-person NHS-Galleri trial, three rounds of screening did not reduce stage III or IV cancers versus usual care. A fall in stage IV cancers alone leaves the case unproven.
It does not. In a Danish cohort of 657,461 children, vaccinated children had a fully adjusted autism hazard ratio of 0.93; a meta-analysis of 1,256,407 children found no link with MMR, thimerosal or mercury.
Supplement makers sell K2 (menaquinone) for stronger bones and cleaner arteries. The observational signal is real; the randomised trials, so far, mostly are not.
Daily vitamin C does not stop you catching colds and does nothing once one starts. It trims a cold's length by about 8% in adults; for the heart, trials show no benefit.
Pooled trials show a genuine but small fall in blood pressure, around 2 mmHg. The bigger pitches — sleep, cramps, energy, anxiety — run ahead of the evidence.
No long-term trial has tested an all-meat diet. The best direct data is a self-reported survey where people felt better but ran markedly high LDL cholesterol — the signal that should give pause.
Two controlled studies compared vitamins in fresh and frozen fruit and vegetables. Frozen matched fresh in most cases and sometimes beat it, especially against fresh produce that had spent a few days in the fridge.
Rumination — replaying the same worries on a loop — is a genuine risk factor for depression, and the best trials show it can be trained down, though no single technique clearly beats the rest.
The best single randomised trial found morning light beat a sham device over eight weeks, but the effect is most reliable when light is added to an antidepressant rather than used alone.
No. A controlled study found orgasm did not change testosterone, and in two large cohorts more frequent ejaculation tracked with slightly lower — not higher — prostate cancer risk.
The TRAVERSE trial cleared its cardiovascular safety in 5,246 high-risk men; the Testosterone Trials found a real but moderate sexual-function benefit. Guidelines reserve it for genuine, twice-confirmed deficiency.
Creatine is not a testosterone booster — the trials show it leaves testosterone unchanged. The baldness scare traces to a single 20-man study that found a rise in DHT, a result no one has replicated in 15 years.
Two things you do in bed have randomised evidence for nocturnal reflux: raising the head of the bed cut acid exposure from 21% to 15%, and a device that kept people on their left side nearly doubled treatment success.
The trials behind facial masks are small, brief and mostly run by the products' makers. They can show a real hydration and comfort effect — but not the lasting anti-ageing results on the packaging.
A cough that outlasts the cold is normal: studies put the average at more than two weeks. Little in the pharmacy reliably shortens it, and antibiotics do not — but some symptoms are a reason to see a doctor.
Plain fizzy water hydrates about as well as still water and is far less corrosive to teeth than juice or soft drinks. The cautions are narrow: flavoured versions and cola, not carbonation itself.
Air-popped popcorn is a whole grain, high in fibre and low in fat — a legitimately good snack. What turns it unhealthy is butter, oil, salt and portion size, not the corn itself.
For people whose pancreas cannot make enzymes, replacement therapy is proven in randomised trials. For healthy people with bloating, the flagship study is a single-arm survey of customers who bought the product online.
TikTok's 'liquid gold' is real cow's first-milk, rich in antibodies and growth factors. But the robust human evidence sits in specific gut conditions, not the immunity, skin and hair benefits sold to healthy adults.
An observational study across four DR Congo outbreak sites estimates that a third of positive mpox PCR results reflect environmental viral DNA, not infection — and that a stricter cutoff fixes most of it.
Insecticide shampoos increasingly meet resistant lice. Trials favour physical treatments — a silicone lotion and methodical wet combing — that lice cannot evolve around.
The system sorts feverish under-5s into red, amber and green. Validation studies find it misses serious illness and over-refers the well — a prompt, not a reliable test.
Fever is often the only clue in a young child, a properly collected urine sample confirms it, and most cases clear on a short antibiotic course. Preventive antibiotics cut recurrences but breed resistant bugs.
With influenza, virus shedding starts within a day of infection, peaks on day two and lasts about five days on average — often before you feel your worst. Nearly a quarter of infections cause one symptom or none at all.
Cochrane reviews found no trials specific to acute neck pain, and only moderate evidence that targeted exercise helps the chronic kind. Manipulation and mobilisation come out roughly even.
Mostly how concentrated it is: pale means well-hydrated, dark means less so. But a few colours — especially red or pink — are signals to get checked rather than to interpret at home.
US preventive guidance recommends against a resting or exercise ECG in symptom-free adults at low cardiovascular risk, and finds the evidence insufficient at higher risk. The tracing rarely changes treatment.
Open-label follow-up of the phase 3 LUNA3 trial shows rilzabrutinib's platelet responses were durable and sometimes appeared in people who had not responded at first — but a minority reached the mark.
Two randomised UK trials tested giving the vaccines together. Systemic reactions stayed mostly mild and immune responses held up, though one trial saw more sore arms and a dip in COVID antibodies with co-administration.
The honest answer is that early type 2 diabetes usually has no signs you can feel. The classic symptoms arrive late, and damage can be under way years before the diagnosis is made.
The injected vaccine contains no live virus. In a Cochrane review, inactivated vaccines raised fever only from 1.5% to 2.3%, and a randomised crossover trial found no excess systemic symptoms over saline placebo.
Yes — the hormones released under stress push glucose up, which is why steroids and severe illness cause hyperglycaemia. Whether everyday stress raises long-term diabetes risk is a smaller, murkier effect.
Colds come from viruses, not cold air. But chilling the body and breathing cold air can blunt the nose's antiviral defences enough to tip a lurking infection into symptoms.
Consistent condom use cuts HIV transmission by about 80% and sharply reduces genital HPV, but offers only about 30% protection against genital herpes. The gap is about how each infection spreads.
If a choking person can still cough or speak, let them cough. If they cannot, the guideline sequence is five back blows then five abdominal thrusts, repeated — and new data suggests bystander action changes who survives.
A French study of 11,558 patients without heart failure linked atenolol to fewer cardiovascular events than bisoprolol. It is observational, so it shows an association, not proof one is better.
EndeavorRx is a prescription game the FDA cleared in 2020 for children with ADHD. Its pivotal trial moved a computer attention score, but the FDA says it may not help the behaviour parents notice.
Software that interprets cardiotocography in labour lifts clinicians' accuracy in reader studies. The largest randomised trial of computerised interpretation, in 47,062 women, found no benefit for mothers or babies.
In the CREST-2 trials, stenting or surgery added to intensive medical treatment left cognition no better at four years than medical treatment alone in people with severe asymptomatic carotid stenosis.
In people with healthy kidneys, trials find high-protein diets do not worsen kidney function. The picture changes for those who already have reduced function, where animal protein may speed decline.
A systematic review of human trials found the evidence weak and inconsistent. Where MSG seemed to trigger headaches, it was given in large doses dissolved in water without food, in studies that were not properly blinded.
A gratitude habit gives most people a genuine but small lift in wellbeing — a 2025 meta-analysis of nearly 25,000 people put the average effect at a modest 0.19 — and its unique benefits are probably overstated.
A network meta-analysis of 118 trials and 31,195 men found every oral PDE5 inhibitor beat placebo, with tadalafil ranked most effective. Guidelines make the tablets, after a health check, the first-line choice.
The beauty claims for silk pillowcases — fewer wrinkles, less acne, smoother hair — have no direct trials behind them. The most rigorous test of silk fabric on skin, in eczema, found it added nothing.
The dripping-mucus feeling is one of the commonest causes of a lingering cough. What clears it depends on the cause — and for allergy, steroid sprays beat antihistamine pills for the drip itself.
The advice to look 20 feet away for 20 seconds every 20 minutes is everywhere. A two-week trial in symptomatic computer users found it cut eye-strain and dry-eye symptoms, but changed no measurable sign of eye health.
A nine-man study found hair fibres thickened from 0.085 to 0.092 mm after 24 weeks of daily massage. The larger dataset was a self-reported survey — run by a hair-loss website.
In a study of 633 people with gout, eating cherries over two days was linked to a 35% lower risk of a flare. It is suggestive, observational evidence — no randomised trial has yet confirmed it.
A varied diet covers most of the 13 essential vitamins. The evidence-based exceptions are specific: vitamin D is hard to get from food, older adults and vegans need B12, and folic acid is advised before pregnancy.
A randomised trial found ordinary ibuprofen cut acute mountain sickness from 69% to 43% on a fast ascent. A Cochrane review found most supplements and pre-acclimatisation gadgets do not hold up.
Most newborn jaundice needs no treatment. The reason clinicians watch it is a rare progression to brain injury — a burden that falls overwhelmingly on poorer countries.
The stitch has a clinical name — exercise-related transient abdominal pain — and decades of study. It is probably not trapped wind or a cramping diaphragm, and a big meal beforehand makes it far more likely.
US preventive guidelines back a blood-sugar test for adults 35 to 70 who carry extra weight; the main diabetes body would test every adult from 35. The gap is about how wide a net catches enough real disease.
A 2006 Cochrane review found the classic ingredient, potassium, only patchily convincing. A newer network meta-analysis of 32 trials is firmer: stannous, potassium and arginine toothpastes can be recommended for pain.
A Cochrane review of 24 trials found surgery beats non-surgical care at stopping an ingrown toenail coming back; adding phenol to the operation cut recurrence from 41% to 14% in the one head-to-head study.
Nausea in early pregnancy is common and usually mild. Ginger has the best trial support for nausea, vitamin B6 and doxylamine are options, and acupuncture shows no clear benefit.
The chronic skin disease is often missed for years. In a cohort of 507 women, those who kept up topical steroid treatment developed no vulval cancers; those who did not had a 4.7% rate.
A jog and a few stretches has thin evidence for cutting injuries. Structured programmes that add strength and balance work — like the FIFA 11+ — cut football injuries by roughly a third in trials.
A systematic review of 38 studies rated the evidence that continuous white noise improves sleep as very low, and warned it may worsen sleep for some. A few small studies do find a benefit.
Across the trials, the best-supported remedy is melatonin taken near destination bedtime after crossing several time zones. Light exposure is the other real lever; sleeping pills chase the symptom, not the clock.
In the 2,137-participant PrEggNut trial, mothers who ate a diet rich in eggs and peanuts through pregnancy and breastfeeding had infants with the same allergy rate as the comparison group.
An independent 2026 meta-analysis of AAV micro-dystrophin trials found small, mostly uncontrolled functional benefits — largest in the youngest boys — set against serious harms including rare deaths.
A small 1990s trial hinted selenium supplements cut cancer, launching a supplement boom. The much larger SELECT trial found no benefit — and signals of harm, including more type 2 diabetes.
A critical review went looking for clinical proof that commercial detox diets remove toxins or keep weight off. It found almost none, and no randomised trial of a commercial detox diet in humans at all.
Diets rich in colourful fruit and vegetables track with less cancer, so supplement makers bottled beta-carotene. Two large trials in smokers found the pills raised lung cancer and death — the opposite of the hope.
The idea that sleep flushes toxins from the brain rests largely on mouse experiments. A 2024 study using the same animal measured the opposite direction, and none of it has been shown in humans.
European screening cut prostate-cancer deaths by 21% at 13 years, at the cost of overdiagnosis; a UK trial of a single test found no mortality benefit. US guidance now makes it a personal choice for men 55 to 69.
The bestselling herbal for an enlarged prostate flopped in the trials: even at triple the usual dose it beat placebo by nothing. The hair-loss claim rests on a handful of small, weak studies rather than proof.
Red-light masks and panels promise photorejuvenation without lasers or needles. A randomised trial of 136 volunteers backs the collagen claim — but it is one good study, and 'red light' covers very different devices.
Saline nasal irrigation has better evidence than most self-care remedies: trials support it for chronic sinus and hay-fever symptoms, and a pilot found it shortened colds. The catch is that the quality is low.
A BMI over 30 flagged obesity in 19.1% of US men, but measured body fat found it in 43.9%. A 58-expert Lancet commission now says BMI alone should not diagnose obesity in an individual.
Warm steam feels good on a blocked nose, but the randomised evidence for heated, humidified air treating a cold shows no clear benefit. A humidifier is comfort, not cure — and a dirty one carries its own risk.
True dietary magnesium shortage in healthy people is rare, and reference guidance does not currently advise supplements. The clear deficiencies come from illness, alcohol and certain drugs, not a missed daily pill.
Dandruff is the mild end of seborrhoeic dermatitis, and Cochrane reviews of that condition back the medicated-shampoo ingredients: ketoconazole and ciclopirox clear flaking better than placebo.
The warning that olive oil's low smoke point makes it unsafe to fry with is largely wrong. Oxidative stability, not smoke point, is what matters, and olive oil is among the more heat-resistant common oils.
The popular claim is that a shot before meals fires up digestion. The controlled measurement shows vinegar slows the stomach down — helpful for blood sugar, unhelpful if you already digest slowly.
On ten monitored flights, passengers away from a sick traveller faced low transmission risk, and every air sample tested negative for common viruses. Measles is the exception that proves the rule.
Bringing up milk is normal in healthy babies: it peaks around four months and usually fades by the first birthday. Most infants need no medicine, and the evidence for acid-suppressing drugs in simple reflux is weak.
Croup gives young children a barking cough and noisy breathing. It is usually mild and self-limiting, and a single dose of oral steroid shortens it — with a low dose working about as well as a high one.
Regular moisturisers and short courses of topical steroids are the mainstays, with modest trial support. Most children improve with age, and popular add-ons like bleach baths are no better than plain water.
A meta-analysis of four small trials found zilebesiran lowered office systolic pressure by 7.16 mmHg versus placebo, with wide confidence intervals, a hint the effect wanes by six months, and more hyperkalaemia.
Commercial full-body scans promise early detection to people with no symptoms. The data show they find something to chase in nearly half, and cancer in about one in a hundred.
Stones form when urine gets too concentrated. The best-tested defence is dull: drink enough that urine stays dilute. In one trial, that alone roughly halved recurrences.
Topical diclofenac and ketoprofen beat their carrier gels for knee osteoarthritis pain, with about 60% of users reporting much less pain. A large network meta-analysis now rates topical diclofenac a first-line option.
H. pylori infection and NSAIDs are the two most common causes of peptic ulcers. Treatment now turns on antibiotic resistance, which is quietly reshaping the first-line regimens.
The old RICE drill was never built on strong trial evidence, and newer guidance drops the ice and anti-inflammatories. The durable parts are protection, gentle loading and time.
The evidence-based first move for a burn is unglamorous: hold it under cool running water. A large registry study links proper cooling to fewer skin grafts and ICU admissions; ice and butter belong nowhere near it.
For most of the world the ability to digest milk sugar declines after weaning, set by a single gene variant. About 68 percent of people have lactose malabsorption.
Sun-driven brown patches are hard to shift. A Cochrane review found a triple-combination cream beat hydroquinone alone; newer meta-analyses point to tranexamic acid and PRP, on thinner evidence.
Haemorrhoids affect about 1 in 20 Americans and half of over-50s. A meta-analysis found fibre cut the risk of persisting symptoms by 47 percent and of bleeding by half.
Gallstones affect 10 to 15 percent of Americans, but stones that never block a bile duct cause no symptoms. Here is when a stone stops being harmless and becomes an emergency.
A pooled study of 1.44 million adults links activity to lower risk of 13 cancers — but not all, and not melanoma. A 2025 randomised trial now shows exercise after colon cancer improves survival.
A Cochrane review of 36 trials found no strong evidence that any spray, gel or lozenge reliably relieves dry mouth. A second review found acupuncture no better than a placebo. The honest answers are narrow.
Artificial tears are still the mainstay, but the trial evidence cannot say which brand is best. A 3,000 mg fish-oil study in 535 people found no benefit over an olive-oil placebo.
The strongest rinse, chlorhexidine, clearly cuts plaque and gum inflammation — but stains teeth, so it is a short-term treatment, not a daily habit. Everyday rinses help less, and always work on top of brushing.
A Cochrane review found lumbar supports do not prevent back pain and their treatment value was unclear. A new French randomised trial found a soft belt added to usual care modestly improved pain and disability.
Under Article 6, AI that is or sits inside a device already needing an independent safety check counts as high-risk. A 70-study review finds the trouble is overlap with existing device law.
Waking up drenched is common and, the best review found, usually nonspecific — not a sign of shortened life. In women the leading identifiable driver is the menopause, which can last far longer than most expect.
The reflex that stands body hair on end in the cold or at a stirring piece of music is largely a leftover from furrier ancestors — but new work shows the same wiring quietly keeps hair able to regrow.
The line is marketing, not trial data. A meta-analysis of 13 randomised trials found adding breakfast raised daily calories and, if anything, nudged weight up, not down. A controlled feeding trial explains why.
Six months of dietitian sessions aimed at a high-fibre diet nudged diet quality but left estimated 10-year cardiovascular risk, HbA1c, cholesterol and blood pressure essentially unchanged versus standard care.
Meta-analyses found calcium pills raised heart-attack risk by around a quarter. A later review — funded by an osteoporosis foundation — found no such link. The disagreement is the story.
A study of 3,932 athletes found cyclists had no worse erectile or urinary function than swimmers and runners. But heavy saddle time is tied to genital numbness, and men logging 5+ hours a week showed lower sperm counts.
One cohort tied high animal protein in midlife to higher mortality, yet found the opposite after 65. Guidelines urge older adults to eat more, and plant protein looks best. No trial proves a lifespan effect.
Classic B12 deficiency is relatively uncommon, but it clusters: in people over 50 whose absorption fails, in vegans whose intake does, and around metformin, acid-lowering drugs and stomach surgery.
A 2019 pooling of 12 trials rated peppermint oil safe and effective for IBS, with a number-needed-to-treat of three. The largest, most rigorous trial then missed its primary endpoint against placebo.
Manual lymphatic drainage is a real physiotherapy for swelling after breast-cancer treatment, where trials show modest, mixed benefit. For 'detoxing' or slimming a healthy body there is no evidence.
The belief that a razor makes hair return coarser, faster or darker is one of medicine's durable myths. Controlled studies going back decades find no change in thickness, colour or growth rate.
Colder days track with more heart attacks in nationwide data, and the sharpest signal is the day after heavy snowfall — a rise seen in men but not women, pointing to the shovel as much as the temperature.
A harmonised meta-analysis of over a million adults found 60 to 75 minutes of daily moderate activity erased the extra death risk tied to sitting more than eight hours. The catch is how much activity that is.
Every documented case of biotin helping hair involved a deficiency. In people who are not deficient the evidence is absent — and high-dose supplements can skew blood tests, including a heart-attack marker.
The Bristol Stool Form Scale turns an awkward question into a measurable one. Types 3 to 5 are the healthy middle; the shape of your stool tracks how fast it moved through you.
A double-blind trial gave 17,598 people pantoprazole or placebo for three years and tracked pneumonia, fractures, kidney disease and dementia. Only gut infections rose, and only modestly.
Most bad breath starts in the mouth. Cochrane reviews found tongue scraping cuts odour compounds only briefly, and the rinses that work best also stain the teeth.
A Cochrane review of 67 trials found topical allylamines and azoles cure far more foot infections than placebo, with allylamines slightly ahead. Oral pills are reserved for stubborn or failed cases.
US guidelines recommend a one-time ultrasound for men aged 65 to 75 who ever smoked, and advise against it for most women. The split turns on who actually benefits from finding a silent bulge in the aorta.
In a 230-patient randomised trial, self-guided app hypnotherapy produced a 33% pain response versus 48% with an in-person therapist and 22% with education — falling short of non-inferiority.
The Hypotension Prediction Index warns anaesthetists before blood pressure falls. Three 2026 trials find a plain mean-pressure alarm does the same job, and the algorithm's benefit tracks how hard clinicians treat.
For everyday exercise, food and water replace what sweat takes. The dangerous salt problem in endurance events is usually too much fluid, not too little sodium — and extra salt does not prevent it.
Magnesium is one of the most popular over-the-counter sleep aids, but a 2026 review of the randomised trials concluded the evidence does not support it as a routine treatment for insomnia.
The sugar alcohol in many 'keto' and sugar-free foods is generally recognised as safe. But newer studies tie high blood levels to cardiovascular events and show it makes platelets more prone to clotting.
Honey and table sugar are both free sugars with almost identical calories. Trials hint at small metabolic differences in honey's favour, but the certainty is low and honey is still added sugar to be limited.
Compulsively scrolling bad news tracks with worse mental and physical health — but the strongest studies show association, not proof, and the scariest prevalence figure shrank by half on replication.
Nocturia is usually blamed on the prostate, but the commonest driver is the kidneys making too much urine overnight. In one trial, low-dose desmopressin trimmed nightly voids and bought about 40 extra minutes of sleep.
Observational studies robustly link the diet to lower mortality. The best randomised trial measured fewer heart attacks and strokes, and the strongest review finds the evidence for a survival benefit weak.
Real deficiency shows as bone pain, muscle weakness or, in children, rickets. But US surveys suggest most people meet their needs, and both a 2011 and a 2024 review advise against routine testing in healthy adults.
For heat exhaustion, rest and shade usually suffice. For heat stroke, a meta-analysis of 63 studies found immersion in cold water cooled the body faster than anything passive — the intervention the evidence agrees on.
Narrative reviews call it promising for scars and wrinkles. A Cochrane review of 24 trials rated the controlled evidence very low quality — and home dermarollers add an infection risk clinics design out.
Taken as prescribed, oral PrEP cuts the risk of getting HIV from sex by about 99%, the CDC says. But randomised trials measured 44% to 86% — because the protection depends almost entirely on taking it.
VITAL, with 25,871 adults, and D-Health, with 21,315, both tested vitamin D against placebo. Neither cut cancer incidence or cancer death — and one saw a signal pointing the wrong way.
Cochrane reviews of paracetamol, ibuprofen and aspirin for tension-type headache find each beats a dummy pill for a minority of people — a real but small effect, with side effects no higher than placebo.
SOLARIO randomised 500 patients after orthopaedic infection surgery to short or long systemic antibiotics. With a local-antibiotic carrier in place, the short course was noninferior and caused fewer side effects.
These soft flaps are harmless. Their real interest is metabolic — one study tied them to diabetes with an odds ratio of 1.89 — but a 2026 cohort found no link to prediabetes. Removal is cosmetic, not a home job.
Two Cochrane reviews found that for ordinary acute low back pain, advice to rest in bed is slightly worse than advice to stay active. For sciatica, it makes little difference either way.
An umbrella review of 41 systematic reviews found sitting, standing and 'bad' posture are at most weakly and inconsistently linked to low back pain — and none of it establishes that posture is the cause.
When brief vertigo is triggered by rolling over or looking up, it is usually a loose crystal in the inner ear. A Cochrane review found a repositioning manoeuvre resolved it in 56% versus 21%.
Common advice says scrape a bee stinger out, never pinch it. The actual evidence says the method barely matters — what counts is speed, because venom keeps pumping every second the stinger stays in.
Amycretin, a single molecule that activates both the GLP-1 and amylin receptors, produced up to 24.3% weight loss over 36 weeks in a 125-person study. The primary goal, though, was safety — not weight.
Two systematic reviews point the same way: for the pill, IUDs, implants and most methods, about 8 in 10 women conceive within a year of stopping — similar to using no method at all.
Cognitive behavioural therapy is one of the few non-hormone options the North American Menopause Society backs at its top evidence level. What it changes is how much flushes bother you, not the thermostat.
Long seen as a disease of women over 40 found only at hysterectomy, it turns up on ultrasound in about one in five gynaecology patients — and every option short of surgery controls symptoms, not the disease.
In HIMALAYA, 305 people with ALS took the RIPK1 inhibitor SAR443820 or placebo; function fell almost identically in both, and the sponsor is halting the drug in ALS.
The US banned Red No. 3 in 2025 on a rat-specific cancer finding, not human data. The separate question — whether dyes affect children's behaviour — has better, and more unsettling, evidence.
Large cohorts link higher optimism and a stronger sense of purpose to longer life and lower mortality, in a dose-dependent way. But the studies are observational, and no trial has proved the causal arrow.
A single randomised trial found rosemary oil and 2% minoxidil produced statistically indistinguishable hair counts at six months. It is the strongest evidence rosemary has — and it is thin.
Chronic hives can flare for months with no allergy to find. A Cochrane review of 9,759 people found modern antihistamines such as cetirizine clear them in a minority, not everyone.
A Cochrane review of 51 trials found powered brushes cut plaque and gum inflammation more than manual ones, on moderate-quality evidence. An 11-year cohort suggests the small edge adds up: fewer teeth lost.
Across 17 randomised trials, blue-light filtering lenses showed no clear benefit for eye strain, vision or sleep. The evening-screen problem they target is real; this is not the fix.
A multicentre reader study found AI raised early-career dentists' caries sensitivity from 67% to 82% without more false positives. Independent testing shows the same tools still miss early lesions.
The pruning of fingertips in a long bath is an active job done by the sympathetic nerves, not water soaking in. Whether the wrinkles are useful is a genuine, unresolved argument.
Two laboratory studies that dropped food onto contaminated surfaces found bacteria transfer within a second. How much moves depends far more on the food and the surface than on the count of five.
Scans confirmed that adults keep heat-producing brown fat, switched on by cold and linked to better metabolic health. Whether you can build enough of it to matter for weight is far less certain.
The RAPID pathway would issue a proposed national coverage decision the day a device clears the FDA, cutting a process that normally runs 9 to 12 months. The trade-off is evidence.
Adults need about 2.4 micrograms a day, and most meat-eaters get it easily. Real deficiency clusters in older people, whose absorption fails, and in vegans, whose intake does.
High-heat cooking makes compounds that damage DNA in the lab — heterocyclic amines, PAHs and acrylamide. The catch is that human diet studies have mostly failed to find a consistent cancer link.
Iron does leach from a cast-iron pan into food, and randomised trials in iron-deficient populations found it raised haemoglobin. The effect depends on what you cook, and means little for people who are iron-replete.
US national survey data put lifetime binge eating disorder at 2 percent of men and anorexia at 0.3 percent. Men are underdiagnosed, and the male-specific presentation often hides as gym dedication.
Meta-analyses of more than a million people find a U-shaped link between sleep duration and death, lowest around seven hours. But this is observational, and reverse causation is the hard part to rule out.
The old advice to buy the hardest mattress you can find is not what the trials show. A double-blind randomised trial and a systematic review both favour medium firmness.
The puffy 'cortisol face' and the 'cortisol cocktails' sold to fix it lean on 'adrenal fatigue' — a condition a systematic review of 58 studies found no evidence for. True cortisol excess is a diagnosable disease.
Tantrums are normal development, not a failure of discipline. The evidence favours calm, consistent responses and structured parenting programmes, and advises against smacking and shouting.
Iron shortfall is the leading cause of anaemia in young children and is linked to poorer development. Yet the evidence that screening symptom-free toddlers or routinely supplementing them helps their brains is thin.
Guidelines settle on a limit near 200 mg a day — roughly two mugs of coffee. But the underlying studies are observational, and a vocal minority argues there is no clearly safe level.
Pulling out is better than no method but among the least reliable in common use: US data put its first-year failure at 20%. Pre-ejaculatory fluid carried motile sperm in a substantial minority of men studied.
Decades of randomised trials give fluoride toothpaste a prevented fraction Cochrane puts at 24%. Concentration and how you brush change the size of the benefit — but no over-the-counter rival has evidence like it.
In a 142-patient phase 3 trial, 37% reached complete remission on the antibody obinutuzumab versus 6% on tacrolimus at two years. A key kidney-function endpoint was not met, tempering the result.
Inviting people to a single colonoscopy cut 10-year colorectal cancer risk from 1.20% to 0.98%. The reduction in cancer deaths did not reach significance — and only 42% of those invited turned up.
Studies going back decades find no link between habitual knuckle cracking and hand arthritis. One doctor cracked a single hand for a lifetime to prove it — and got arthritis in neither.
In ESSENCE, the first 800 patients with biopsy-confirmed fatty-liver disease were analysed at week 72. Steatohepatitis resolved in 62.9% on semaglutide versus 34.3% on placebo — an interim look at an ongoing trial.
Two trials found low-dose colchicine cut cardiovascular events, and the FDA approved it for heart risk in 2023. Then the largest trial found nothing, leaving the question genuinely unsettled.
Xerosis is a barrier problem, not dirt. Cochrane found moisturisers cut eczema flares 60% and spared steroid use; in care-home residents a twice-daily emollient roughly halved skin tears, on weak evidence.
For adults with no symptoms, the US Preventive Services Task Force recommends against carotid ultrasound screening — a rare 'D' grade, because finding the narrowing does more harm than good.
Pooled across 85 trials, exercise-based cardiac rehab cut later heart attacks and hospital admissions but barely moved death rates within a year — a real benefit, and a narrower one than the usual pitch.
A retrospective analysis of 54,114 women on a digital weight-loss service found those with PCOS lost as much as those without. But only 40 PCOS users reached the 10-month mark, and the data are observational.
Contactless photoplethysmography turns an ordinary camera into a heart-rate monitor, and pooled studies show it tracks pulse well. Oxygen, respiration and the stress scores layered on top rest on far thinner evidence.
The 2024 AASM guideline now advises against routinely using the dopamine agonists that were once standard, because over time they often make the condition worse — and puts anticonvulsants and iron first.
The evidence is real but modest, and stronger for anxiety than for sleep itself. One 120-person trial found a large benefit; pooled analyses across studies find a smaller, more uncertain effect.
A Nature study traced stress-driven greying in mice to sympathetic nerves that deplete pigment stem cells. Separate human work shows some grey hairs regain colour.
Adding the immunotherapy to perioperative chemotherapy improved overall survival in resectable gastric and junction cancer — crossing the significance line the interim analysis had missed.
Around 60–70% of infants carry Clostridioides difficile without illness. A Science study finds its toxins remodel the newborn gut in mice — but the direct human evidence is still limited to cells and biopsies.
Organic produce carries far fewer pesticide residues and modestly more of some antioxidants. But there is no strong evidence that eating organic makes you healthier, and the cancer signal is observational.
In a tightly controlled feeding trial, swapping high-GI for low-GI carbohydrate inside a healthy diet did not improve insulin sensitivity, cholesterol or blood pressure. The wider evidence rates the GI case as weak.
In the largest head-to-head trial, a simpler therapy delivered by junior staff matched full CBT — mean difference 0.1 PHQ-9 points. A Cochrane review finds no difference between the two.
No cream, pill or gel reverses a sunburn or shortens it. Cool compresses, moisturizer and painkillers ease the days it lasts; the burn itself is UV damage that heals on its own.
A meta-analysis of 56 trials and 134,424 children finds RTS,S and R21 cut clinical malaria by about a third overall, with efficacy strongest alongside seasonal chemoprevention and waning after 36 months.
Colic is intense crying in a healthy, well-fed baby that peaks in the first six weeks and eases by three months. Most remedies do little; the best evidence is modest and mainly for breastfed infants.
Most constipation in children has no underlying disease. Guidelines say the treatment that works is a laxative — clearing the backlog, then a maintenance dose for weeks — not simply adding fibre or fluid.
Sold as natural, safer and tailored by hormone testing, custom-compounded menopausal hormones are untested against approved options — and expert panels advise restricting their use.
In a 711-patient phase 2b trial, the myeloperoxidase inhibitor mitiperstat did not improve symptoms or walking distance in heart failure with preserved or mildly reduced ejection fraction.
Cohorts link both to modestly higher rates of heart disease and early death, on low-certainty evidence. A 2019 guideline then told people to keep eating them — and split the field over how to weigh nutrition science.
Large randomised trials mostly find no cardiovascular benefit from ordinary fish-oil capsules. One high-dose prescription drug is the striking exception, and the case for brain protection is weak.
The official figure is 0.8 grams per kilogram of bodyweight a day — but that number is a floor to prevent deficiency, not a target for optimal health, and that distinction drives most of the argument.
Across nearly 1.1 million people, each extra daily cup tracks with lower diabetes risk in a clear dose-response. It is consistent and large — and still only observational.
A Cochrane review of 48 trials found treatment may lift pregnancy rates from about 21% to 22–48%, but couldn't confirm a live-birth benefit. Microsurgery had the fewest recurrences.
A kilogram of muscle burns about 13 calories a day at rest — far less than the fitness-marketing figure implies. But resistance training does nudge resting metabolism up, by roughly 96 calories a day in a meta-analysis.
A short course of a first-line antibiotic clears most uncomplicated UTIs. Five-day nitrofurantoin beat single-dose fosfomycin (70% vs 58% resolution), and two-thirds of women recovered on ibuprofen alone.
Modern techniques fail less than 1% of the time. The best meta-analysis found no link to aggressive or fatal prostate cancer; a 2-million-man registry still sees a small excess, most likely from extra testing.
One drug, dapoxetine, is purpose-approved for it, and not in the US. An umbrella review of 65 trials found the SSRIs and anaesthetics that lengthen latency rest on weak evidence.
An individual-participant meta-analysis found metformin given in pregnancy did not lower the odds of gestational diabetes, though it modestly lengthened gestation and reduced preterm birth.
The old antidepressant is prescribed at low doses for insomnia far more than its evidence supports. A Cochrane review found only a modest, low-certainty effect on subjective sleep and none on measured sleep efficiency.
In the largest pooled cohort studies, the lowest-risk amount of sleep sits closer to seven hours, and both too little and too much track higher mortality. But the curve is a warning sign, not a prescription.
Adding pembrolizumab plus maintenance olaparib to first-line chemotherapy improved progression-free survival — but pembrolizumab added without olaparib did nothing at all.
In PROPEL 3, children on once-daily infigratinib grew 1.74 cm/year faster than those on placebo over 52 weeks. It is a pill, not an injection — but the endpoint is growth speed, not long-term health.
Dopamine is a learning signal that tracks surprise, not a pleasure tank you drain and refill. Stripped of the neuroscience label, the practice is ordinary stimulus control — and that narrower version has some support.
The largest meta-analysis puts the incidence attributable to the drug at about 15% — one in six or seven. Critics who reanalysed part of it put it above 50%. The gap is about what counts as evidence.
Saving starch for the end of a meal reliably blunts the glucose rise afterwards in small trials — but the evidence is short-term, low-certainty, and silent on whether it changes long-term control.
Pooled trials show foam rolling briefly improves flexibility and eases muscle soreness, but its effects on strength, power and recovery are small to negligible — and the injury and 'fascia' claims are unsupported.
Pooled randomised trials show real improvements in skin hydration and elasticity versus placebo, but the effect is moderate, the measures are instrument readings, and the evidence base is shaky.
Randomised trials show lower self-reported stress and anxiety, but the certainty is low, the studies are small and wildly inconsistent, and a separate evidence strand flags liver and thyroid risks.
AIROPLANE enrolled 1,818 newborns at 32 to 35 weeks across 26 Australian hospitals. Starting with 30% oxygen instead of room air left the same share still on respiratory support leaving the delivery room.
A cohort of 5.24 million UK adults linked higher BMI to 17 of 22 cancers — strongly for the uterus, weakly or not at all for others, and inversely for a couple. The pattern is specific, not uniform.
One in five people get chronic itch at some point. When no rash and no cause turn up, a Cochrane review found almost no trials at all — leaving guideline experts to work from indirect evidence.
In QWINT-1, fixed-dose weekly efsitora cut HbA1c about as much as daily glargine in 795 insulin-naive adults — with a lower rate of significant hypoglycaemia and a quarter of the dose changes.
Alpha-blockers ease symptoms within weeks; 5-alpha-reductase inhibitors shrink the gland over months. In a 3,047-man trial, combining them cut progression risk by 66%. Newer office procedures spare sexual function.
The familiar explanation — dehydration and lost salts — is the weakest part of the evidence. The better-supported idea is that cramping is a failure of nerve control, which is why a mouthful of pickle juice can stop one.
In a 258-patient phase 3 trial, the oral drug reduced transfusion needs in about 30% of adults with transfusion-dependent thalassaemia, versus 13% on placebo.
A large study of energy use across the lifespan found it holds steady from age 20 to 60, once body size is accounted for. The midlife metabolic slump is mostly a myth; the decline comes later.
In a study of 750 women, those with 'low' ovarian-reserve hormones were no less likely to conceive. Professional guidance says the test shouldn't be used to counsel women who aren't already infertile.
A smartphone app delivering CBT cut tinnitus-related distress about 20 points more than a sham app in 60 adults, and the effect held for two months. The trial was small and industry-funded.
Medicare paid over $500 million for remote monitoring in 2024, but a watchdog found 43% of patients didn't get the full service — and rigorous evidence that it improves outcomes remains limited.
Reviews find portals may improve awareness and the patient–doctor relationship, with unclear effect on efficiency. Under new US rules, patients now see 40% of results before their clinician does.
23andMe's cleared BRCA report reads 3 of more than 1,000 mutations, so a negative result is not the all-clear it looks like — and the firm's bankruptcy has put customers' genetic data in play.
Sensors and reminder inhalers get patients to take more doses — one trial lifted adherence from 30% to 84%. That this translates into meaningfully better control is real but a smaller effect.
In an 81-child trial, vosoritide raised annualised growth velocity by 2.33 cm a year against placebo in hypochondroplasia, which has no targeted treatment. The endpoint is growth speed, not final height.
A meta-analysis of consumer neurofeedback found no benefit for cognition, mindfulness or physical health and only a small effect on distress — even though the headbands do record real brain activity.
A Danish study of 71,000 cases found the risk factors tied to a diagnosis weakened over a decade, pointing to changing diagnostic practice rather than falling thresholds of impairment.
New at-home molecular tests catch most established colorectal cancers, but find only 13–43% of the advanced precancerous polyps a colonoscopy is meant to remove before they become cancer.
In half a million Chinese adults, higher exhaled carbon monoxide tracked with lower Parkinson's risk even among people who never smoked. It is an association, not a therapy.
A British Columbia study emulated a trial across 41,000 patients. Those started on take-home methadone within weeks to months of induction stayed in treatment longer and died less than those on daily witnessed dosing.
Some steps demonstrably lower the particles and chemicals you take in. Whether lowering them improves health is a question no study has yet answered.
Exposure is real and universal. One human study links plastics in artery plaque to worse outcomes. No causal harm is established, and the measurements are still maturing.
A postpartum smoking programme and a safe-sleep video series each failed the question they were designed to answer. What they reported next is where the interpretation gets difficult.
One found doctors stopped using it as shifts got busier. The other, in 9,691 Kenyan patients, found it safe but no better than the electronic record alone. Neither supports deployment.
Resistance training in adults averaging 75 with vascular cognitive impairment, and aerobic exercise in adolescents. Both beat their control, and both controls were active rather than nothing.
In 17,685 footballers, borderline ECG findings predicted almost no disease. Across 360 studies of female athletes, screening concentrated on mental health while menstrual and pelvic floor health went largely unasked.
OSPREY implanted every participant, then randomly decided whose device was switched on. That design answers a question most implant studies leave open, and it has limits the authors state plainly.
AD109 cut the apnoea-hypopnoea index by four events an hour more than placebo over 26 weeks. It did not improve fatigue, and one in five participants stopped because of side effects.
When researchers screened 101 human studies against basic quality criteria, none met all of them. The field's core difficulty is telling real particles from contamination.
Animal studies show plastic particles disturbing the gut and triggering inflammation. Human evidence is mostly detection, with cause and effect still unresolved.
An arthritis antibody and a diabetes drug were given to depressed patients in 2026 trials. Both were designed to probe a mechanism rather than prove a treatment, and reading them as results would be a mistake.
Two 2026 trials point the same direction: the hardware in depression treatment is mature, and the remaining gains are in precision and in what the treatment costs the patient's memory.
A trial in India found calling tuberculosis survivors was non-inferior to visiting them, on a combined measure. Split into survivors and their contacts, the picture reverses for the group at highest risk.
A six-month regimen for drug-resistant tuberculosis matched the standard of care in South Africa. Four days of antibiotics matched eight in African children hospitalised with severe pneumonia.
4CMenB had shown promise against gonorrhoea in observational data. Randomised, its efficacy was minus 0.5%. In the same field, a once-weekly oral HIV regimen met non-inferiority at 48 weeks.
Zenagamtide was tested as a weekly injection and a daily pill in type 2 diabetes. Both cut HbA1c against placebo at 36 weeks, and the oral version's side effects rose steeply with dose.
Three randomised trials found routine finger-prick testing produced no clinically meaningful change in long-term blood sugar for people whose type 2 diabetes is managed without insulin.
Tranexamic acid cut postpartum haemorrhage in placenta praevia. Dapagliflozin nearly halved acute kidney injury after cardiac surgery. The effect sizes are very different, and so is how much to trust them.
Europe cut its safe intake for BPA by orders of magnitude and banned it in food packaging. US regulators disagree, and the substitutes are less studied.
The best evidence frames procrastination as a way of dodging bad feelings about a task, not a scheduling flaw — and following students over a year, more of it tracked with more depression, anxiety and stress.
Substantial, sustained weight loss can return blood sugar to the normal range without drugs in some people diagnosed recently. It is real, it is not a cure, and it fades as the weight comes back.
The chemistry and the exposure are solid. The headline death tolls are model estimates built on assumptions, and they carry uncertainty ranges to match.
A Cochrane review of 79 trials and 24,308 patients found the primary-care model helps with depression and anxiety, modestly in the short and medium term and not at all in the very long term.
A secondary analysis of the ELITE hormone-therapy trial found hints that social ties tracked with cognition, but none survived correction for multiple testing.
Researchers built an AI pipeline to convert decades of narrative reports into one modern TNM staging system, reaching 95% accuracy for tumour classification in an expert-labelled test set.
Studies have found plastic particles in human blood, placenta and brain tissue. Detecting a particle establishes exposure — not that it is doing harm.
Two small pilot studies in 18-to-25-year-olds found morning bright light on its own shifted circadian timing little, while adding a timed schedule and evening blue-blockers advanced it about 35 minutes.
Patients whose carotid plaque contained plastics had a higher rate of heart attack, stroke or death. It is an association in 257 people, not proof of cause.
Applied to 411,000 UK Biobank adults, the Edmonton staging system and the Lancet Commission's clinical-obesity model classified severe disease alike but diverged on who counts as early-stage.
Five grams a week is the top of a wide range in one 2020 analysis. A mechanistic model put the mass humans actually ingest at micrograms, not grams.
A network meta-analysis of 163 trials found EPA, vitamin D and a St John's wort extract beat placebo by margins so large the researchers treat them as a warning about the evidence, not a green light.
Reviewing and stopping unnecessary drugs in older people is safe in trials and reduces inappropriate prescriptions. Whether it makes them live longer or feel better is far less settled than the enthusiasm implies.
In a randomised trial of 3,102 bypass patients across seven countries, all-cause mortality was near-identical between bilateral and single internal thoracic artery grafting.
Cochrane reviews rate anti-inflammatory painkillers a very effective treatment for menstrual cramps, roughly doubling the odds of good pain relief. Exercise helps too, but on lower-quality evidence.
Trials put the pregnancy rate after emergency contraceptive pills at roughly 1-3%. But the risk rose more than threefold in obese women, and the levonorgestrel pill fared worst of all.
A survey of seven countries found the youth mental health app market dominated by paid journaling and meditation apps. The AI-powered ones show early promise on symptoms — and none had checked for harm.
In 264 patients in China, the device maker's trial reported clinical worsening in 25.7% versus 51.5% on medical therapy alone (HR 0.49) — but no sham procedure blinded patients.
Cochrane's 2024 review found low-certainty evidence of a small effect since fluoride toothpaste became widespread. The IQ meta-analysis that reopened the argument reported a null below 1.5 mg/L in one key analysis.
The human intestinal-permeability literature lists endurance exercise, NSAIDs, pregnancy and surfactants as stressors. Coffee is not on that list, and alcohol's case is largely inferred.
US guidelines recommend routine chlamydia and gonorrhea screening for sexually active women under 25 and older women at higher risk. Self-collected swabs match clinician-collected ones closely.
The phase 3 VALOR trial met its primary endpoint at the higher dose of the oral TYK2-JAK1 inhibitor, with more serious infections — a benefit and a safety signal that arrive together.
Twelve studies in 1,158 IBS patients found gut-directed hypnotherapy improved symptoms, with the firmest results in high-volume and group delivery. The microbiome route is weaker.
A Cochrane review found women doing pelvic floor muscle training were eight times more likely to report their stress incontinence cured than untreated women — with the strongest evidence for that one condition.
A review in Gut says no intestinal disease can be cured by normalising barrier function, and that it is unproven whether restoring the barrier improves any clinical outcome at all.
ITACS randomised 955 anaemic adults to intravenous iron or placebo before elective cardiac surgery. Fewer patients needed a transfusion, but the primary benefit was a median of one day alive and at home.
A Copenhagen team has just published the protocol for the first study designed to test whether reducing PFAS exposure changes anything. That it is still a protocol tells you where the evidence stands.
A Cochrane review of 50 trials found cranberry products lower UTI risk in women with recurrent infections and in children, but no benefit in the elderly, in pregnancy, or in bladder-emptying problems.
A joint AGA and ACG guideline graded ten treatments for chronic constipation. The cheap osmotic laxative and the newest secretagogues sit in the same recommendation tier.
RACER-Knee masked patients with sham incisions and found a Forgotten Joint Score difference of −1.5 points at 12 months (P=0.62) — while the robotic operation cost more.
Hormones, surgery and painkillers can reduce pain and improve fertility, but none reliably alter the disease itself — and even removing the uterus does not guarantee the disease goes with it.
Observational studies had linked proton pump inhibitors to fractures, dementia, kidney disease and more. A randomised trial collected all of those outcomes and found only enteric infections.
The 2023 global guideline puts lifestyle first for everyone, letrozole first for fertility, and the pill for cycles and excess hair — while rating much of its own evidence low to moderate quality.
An umbrella review graded 249 effect sizes across 67 risk factors for male infertility. More than half were rated very low certainty — and the review contradicts its own table on one of them.
It found rising microbiome diversity and falling inflammatory markers in the fermented-food arm — and no change in its own primary outcome in the high-fibre arm it was compared against.
A once-daily experimental pill beat placebo in a phase 3 trial and is under regulatory review — yet no study has tested its claimed edge over older dopamine agonists head-to-head.
A study of 19,539 patients echoed the randomised CONVINCE trial — but it was observational, and several of its authors work for the dialysis company that owns the data.
In two large clinics, the live birth rate per woman who returned to use her eggs was around 39-50% under 35 or 38, but far lower for older women — and most women who froze never came back to use them.
The radioligand cut the risk of radiographic progression or death by 28% when added to standard therapy in a phase 3 trial — a real but incremental gain, bought with more side-effects.
The first randomised trial to pit surgery against the natural course of big-toe arthritis found fusion cut walking pain to 1.3 on a 10-point scale at one year, versus 5.7 with watchful waiting.
In modern couples timing intercourse, an estimated 18% of women aged 35-39 failed to conceive within a year — not one in three. The most alarming figures come from models, not from watching real couples try.
A 2026 meta-analysis of nine in vitro studies found a small, outlier-sensitive reduction in enamel microhardness. Every study was done on extracted teeth. The better-evidenced problem is sensitivity.
Two randomised trials in more than 1,800 children found no benefit in acute gastroenteritis. A Cochrane review of 23 trials found fewer upper respiratory infections, on low-certainty evidence.
US government metrologists sent one homogenised faecal standard to seven consumer testing services. Species counts came back ranging from 20 to 1,701 for the same material.
In a 22,785-user study of one temperature-based app, typical use failed 6.9 per 100 woman-years and perfect use 1.0 — but the study came from the maker, and traditional methods vary widely.
A systematic review in Cell called that rate implausible and said it overstates the gut microbiome's role in human disease. A separate audit found the statistical tools themselves disagree.
GLORY-2 randomised 461 Chinese adults with obesity to a weekly GLP-1/glucagon dual agonist or placebo; weight fell 16.65% versus 1.50% at 60 weeks, alongside high rates of nausea and vomiting.
A million-woman Danish cohort found a modest rise in antidepressant use among hormonal contraceptive users. A Cochrane review of weight found no evidence the pill causes weight gain.
A network meta-analysis of 13 randomised trials put the diet ahead of every alternative for IBS symptoms. Its authors note the trials skipped reintroduction and personalisation entirely.
Dazukibart eased skin and muscle disease within weeks and held up for nearly two years — but the trials were tiny, manufacturer-run, and the makers say a phase 3 is needed to confirm it.
A network meta-analysis found six treatments clearing the clinically important threshold in the short term. It also graded 98.6% of the evidence very low certainty, and found nothing that held up past a year.
A prespecified analysis of the ATTRibute-CM trial found the TTR-stabilising pill slowed the decline in how patients rated their own health, with a number-needed-to-treat of six to keep one 'not worse'.
An umbrella review of 41 systematic reviews found no consensus that posture causes back pain. And correcting posture reliably changes alignment — but not, consistently, pain.
Two Cochrane reviews found low- to very low-certainty evidence that floss slightly reduces gum inflammation. Neither found a single trial measuring interproximal decay, the thing flossing is sold to prevent.
The numbers most methods advertise are perfect-use figures from clinical trials. In everyday use the pill fails about seven users in 100 a year, the condom about 13, withdrawal about 20.
Patients in remission who stayed on the JAK inhibitor through a second year flared far less than those switched to placebo — 7.4% versus 59.5% — in an extension of the SELECT-GCA trial.
The final HARMONi-A analysis reports a 2.7-month gain in median overall survival — 16.8 versus 14.1 months — for the PD-1/VEGF bispecific added to chemotherapy in a China-only phase 3 trial.
The SMART trial tested clesrovimab against palivizumab in premature and heart- and lung-affected infants. It was built to show safety, not to prove one prevents more RSV than the other.
A randomised-withdrawal trial showed the antibody-lowering drug kept CIDP patients in remission. A 2026 extension reports lasting benefit, but with no placebo group to measure it against.
Canker sores clear on their own, and nothing reliably cures or prevents them. A Cochrane review found systemic drugs unproven; some topical options may ease pain, but the trials behind them are small and weak.
The targeted combination more than tripled progression-free survival versus placebo in iodine-refractory disease — but overall survival is not yet significant and the trial was mostly Asian.
Adding the antipsychotic to an antidepressant beat placebo in two phase 3 trials. But the dose that worked in one failed in the other — a wrinkle worth carrying into the prescription.
In 328 patients with third-generation cephalosporin-resistant gut bacteria in the blood, an old, narrow-spectrum antibiotic met its non-inferiority mark, offering a way to spare carbapenems.
In the head-to-head OVERLORD-MS trial, 92.2% on rituximab and 94.8% on ocrelizumab had no new MRI lesions from months 6 to 24, meeting the prespecified bar for noninferiority.
In DigiSep, adding metagenomic sequencing to standard cultures did not improve the main 28-day outcome, though ventilation time and shock resolution were shorter in exploratory analyses.
Oral paltusotine kept median IGF-I near the normal ceiling through week 207 in an open-label extension, but only 20 of 43 patients remained by then and the study had no comparison group.
REMEASURE randomised 73 patients to Kono-S anastomosis or mesenteric resection after ileocolic surgery for Crohn's disease; endoscopic recurrence at six months was 33% versus 32%.
In ATTRACTION, tirofiban given after successful thrombectomy left more stroke patients independent at 90 days than placebo, though symptomatic brain bleeds trended higher and were not significantly different.
Guidelines say earwax that causes no symptoms should be left untreated. When wax truly blocks the ear, drops, irrigation or clinician removal help, but ear candles, when tested, removed no wax and caused injuries.
In a 500-patient ICU trial across seven countries, bicarbonate infusions for metabolic acidosis in patients on vasopressors did not lower major kidney events or death at 30 days.
Final ALIGN results show the endothelin blocker preserved kidney function over 2.5 years in a rare kidney disease, yet the difference at week 136 just missed statistical significance (p=0.057).
In a UK trial of 1,956 critically ill adults, neither carbocisteine nor nebulised hypertonic saline shortened time on a ventilator, and each was tied to a specific harm.
In the FIND-CKD trial, non-diabetic patients on finerenone lost kidney function at 3.3 versus 4.0 ml/min/1.73 m² a year — a small edge that extends a diabetes drug to a new group.
In a 122-patient South African proof-of-concept study, a four-month all-oral combination of quabodepistat, delamanid and bedaquiline cleared TB from sputum as often as the six-month standard.
In the phase 3 GCAptAIN trial the interleukin-17A blocker did not significantly beat placebo for sustained remission at one year, leaving the IL-6 inhibitor tocilizumab as the proven steroid-sparing option.
The anti-alpha-synuclein antibody did not significantly delay motor progression in the phase 2b PADOVA study, though a non-significant trend and secondary signals keep a phase 3 trial alive.
Two GSK-funded phase 3 trials found roughly 20% of patients on bepirovirsen reached a functional cure at 72 weeks versus none on placebo — alongside more adverse events and liver-enzyme rises.
Two large trials of the anti-ST2 antibody gave discordant results: a modest signal in the phase 2b study, and a missed primary endpoint for the same dose in the confirmatory phase 3.
The nosebleed guideline first move is specific: firm, sustained pressure on the soft lower third of the nose for at least five minutes. Most settle this way; the treatments people escalate to have thin evidence.
In the phase 3 Integral-1 trial, cefepime plus the new β-lactamase blocker nacubactam cured 82% of complicated urinary infections versus 61% for imipenem, offering a way to spare carbapenems.
Pooled trials find forest therapy lowers stress, anxiety, and blood pressure short-term. But heterogeneity is high and reviewers grade the certainty as low to very low.
In VERITAC-2 the oral degrader more than doubled progression-free survival over fulvestrant in patients with an ESR1 mutation — 5.0 months versus 2.1 — but not in the trial as a whole.
PRoMPT BOLUS, a 9041-child trial across 47 emergency departments, found kidney-injury events at 30 days in 3.4% on balanced fluid and 3.0% on saline (P=0.85) — no meaningful difference.
Cemdisiran, a gene-silencing drug given under the skin once every three months, cut daily-living scores more than placebo in antibody-positive generalised myasthenia gravis, a rare complement-driven disease.
Most hiccups stop on their own, and the remedies everyone swears by have almost no trial evidence. The one gadget with published data was studied by its own inventor and funded through the product crowdfunding campaign.
The largest syntheses find apps beat doing nothing on depression and anxiety by about a third of a standard deviation — but the edge shrinks against real treatment, and one umbrella review found no convincing proof.
A 2025 meta-analysis found cold-water immersion cut stress 12 hours later, but not immediately — and its effect on immunity and mood did not hold up.
In 1,362 Shanghai dialysis patients followed for over three years, hemoadsorption plus haemodialysis lowered all-cause mortality versus dialysis alone — a borderline result from an open-label trial.
Relacorilant kept blood pressure under control when patients who had responded were kept on it rather than switched to placebo. The pivotal trial randomised just 62 people.
A meta-regression of 169 trials coded 34 therapeutic ingredients. The most common — psychoeducation, relaxation, mindfulness — were not the ones that best predicted getting better.
In a single-centre trial of 100 patients with decompensated cirrhosis, six months of atorvastatin cut recurrent complications from 72% to 36% — a striking but preliminary result needing larger confirmation.
OCULUS was halted at interim analysis: continuing a GLP-1 or GIP agonist before endoscopy left 25.0% of patients with clinically significant retained stomach contents, versus 3.1% who held one dose.
In the open-label extension of the VIVID programme, remission rates stayed high at 104 weeks — but no placebo group ran alongside, so durability is described, not proven, against nature.
In the COSPIRIT-JIA trial, most children with two stubborn forms of juvenile idiopathic arthritis responded to ixekizumab by week 16 — but the main result had no control group.
In the ALLEGORY trial, 76.7% of patients with active SLE reached the SRI-4 response at 52 weeks on the B-cell–depleting antibody versus 53.5% on placebo, extending a drug already cleared for lupus nephritis.
In the LATITUDE trial, monthly cabotegravir–rilpivirine injections cut regimen failure to 22.8% from 41.2% on oral therapy among people with a history of missed doses, prompting an early stop.
Efimosfermin, an FGF21 analogue given every four weeks, was well tolerated over 24 weeks in 84 patients with fatty-liver disease — but this trial was designed to test safety, not whether it heals the liver.
A transformer model trained on 17,119 scans beat expert and non-expert examiners on every metric and cut simulated referrals by 63%. The catch is who built it and the validation the rest of the field still lacks.